Early Phase 1
N=219
Gabapentin for Perioperative Pain Relief in Surgical Abortion
Pain Control
Bottom Line
View on ClinicalTrials.gov: NCT04292171 ↗Enrolled (actual)
219
Serious AEs
0.0%
Results posted
Dec 2020
Primary outcome: Primary: Pain Score — 17; 17 score on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- Early Phase 1
- Interventions
- Gabapentin (Drug); Placebos (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- Female
- Sponsor
- University of Nevada, Las Vegas
- Primary completion
- Mar 2018
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Pain Score |
17; 17 | — |
| SECONDARY Pain Score 24 |
0; 1 | — |
| SECONDARY Nausea |
1.74; 1.74 | — |
| SECONDARY Vomiting |
0.85; 0.74 | — |
| SECONDARY Pain Score at 30 Minutes Postoperative |
20; 23 | — |
Summary
Gabapentin preoperative use for evaluation of benefit to reduce pain during and after surgical office-based abortion.
Eligibility Criteria
Inclusion Criteria
- Women seeking surgical abortion between 5 and 23 6/7 weeks of ultrasound age.
- English or Spanish speaking
- eligible for office-based surgical pregnancy termination
Exclusion Criteria
- present use of gabapentin or pregabalin,
- renal disease
- sensitivity or allergy to gabapentin
- Missed abortion
Data sourced from ClinicalTrials.gov (NCT04292171). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.